More than 10 million people around the world suffer from Parkinson's disease, according to the Parkinson's Disease Foundation. Unfortunately, pharmaceutical company Merck (MRK 0.53%) announced last week that it will halt the development of an experimental drug for this indication because of disappointing clinical data. Does Merck have other drugs in development for this disease? Are smaller biotechs making progress in this space? Health-care analyst Max Macaluso discusses these questions in the following video.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.